News
ANL
10.52
-3.04%
-0.33
Joseph Pantginis Maintains Buy Rating and $20 Price Target on AN4005’s Durable Responses and Favorable Safety Profile
TipRanks · 3d ago
Weekly Report: what happened at ANL last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at ANL last week (1026-1030)?
Weekly Report · 11/02 09:20
Adlai Nortye’s AN4035 Secures Late-Breaking Oral Slot at EORTC-NCI-AACR Cancer Symposium
TipRanks · 10/28 10:36
Adlai Nortye Group Reveals Oral Presentation For AN4035 Program Update At the Upcoming 38th EORTC-NCI-AACR Symposium
Benzinga · 10/27 20:09
Weekly Report: what happened at ANL last week (1019-1023)?
Weekly Report · 10/26 09:20
Weekly Report: what happened at ANL last week (1012-1016)?
Weekly Report · 10/19 09:20
Analysts Offer Insights on Healthcare Companies: Opko Health (OPK) and Adlai Nortye Ltd. Sponsored ADR (ANL)
TipRanks · 10/15 16:30
Penske Automotive, OPKO Health, Ericsson And Other Big Stocks Moving Higher On Thursday
Benzinga · 10/15 14:12
Adlai Nortye Partners With Lilly And Merck KGaA To Evaluate AN4035 Combination In Solid Tumors
NASDAQ · 10/15 13:04
Adlai Nortye to Work With Eli Lilly, Merck on Trial for Cancer Treatment
Dow Jones · 10/15 12:51
Adlai Nortye Strikes Global Clinical Collaboration with Lilly and Merck for AN4035 Combination Trial
TipRanks · 10/15 11:31
Adlai Nortye Group enters Clinical Trial Collaboration And Supply Agreements With Eli Lilly And Merck KGaA For The ERBITUX Anti-EGFR Antibody
Benzinga · 10/15 11:14
Adlai Nortye enters CTCSAs with Eli Lilly, Merck KGaA for cetuximab
TipRanks · 10/15 11:10
Weekly Report: what happened at ANL last week (1005-1009)?
Weekly Report · 10/12 09:21
Adlai Nortye Group: Only For The Risk-Tolerant After A Massive Rally
Seeking Alpha · 10/08 15:45
Weekly Report: what happened at ANL last week (0928-1002)?
Weekly Report · 10/05 09:21
Major Insider Move Shakes Up Adlai Nortye Sponsored ADR
TipRanks · 10/02 02:02
Adlai Nortye Names Christopher Liu as Head of Investor and Public Relations
TipRanks · 09/30 12:58
Adlai Nortye Shareholders Approve All Resolutions at September 30 Extraordinary Meeting
TipRanks · 09/30 10:28
More
Webull provides a variety of real-time ANL stock news. You can receive the latest news about Adlai Nortye Group Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ANL
Adlai Nortye Group Ltd. is a clinical-stage biotechnology company. The Company is engaged in the research and development of pharmaceutical products. It is developing targeted and immune-modulating cancer therapies. Its RAS-targeting portfolio includes AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate (ADC) delivering a potent pan-RAS(ON) inhibitor directly to tumors. It is also developing cancer immunotherapies, including AN8025, a tri-functional fusion protein (aPD-L1 × CD86 variant × LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005, a first-in-class oral small-molecule PD-L1 inhibitor, which are designed to activate cancer immunity in novel ways. Its pipeline also includes AN0025, a small molecule EP4 antagonist designed to modulate the tumor microenvironment.